Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2001

View Archived Issues

NPY antagonist no longer in development at AstraZeneca

Patient enrollment complete in Spheramine trial for Parkinson's disease

Orphan Medical provides update on drugs nearing approval

ACE inhibitor introduced in U.S. for reducing cardiovascular events in patients at risk

CAT and Elan to develop human antibodies for neurological diseases

Evidence for use of lamotrigine in the control of neuropathic pain presented

Selective aromatase inhibitors show promise in early or preventive breast cancer treatment

Pharmacopeia and Amgen enter two new drug discovery collaborations

Genomics-based collaboration established by ImmunoGen and Avalon

Feasibility study commences for Medusa-delivered relaxin

TC-2559: a neuronal nicotinic receptor ligand expected to have negligible peripheral effects

Tamiflu to be launched this week in Japan

Clinical trials begin in Nairobi with first AIDS vaccine designed for Africa

Phase II results with rFGF-2 in PAD reported

Rivastigmine emerges from recent study as effective and safe therapy for Lewy body dementia

Morphine alternative M6G shows promise in phase II trial

Higher dose Neurontin tablets now cleared for use in Rx of neuropathic pain

Antisoma's TheraFab enters phase I lung cancer trial

Amgen highlights Q4 and full-year 2000 developments

Isoquinolines as inhibitors of If current for cardiovascular disorders

Novel treatments for pain and inflammation identified at Novartis

Antiapoptotic agents designed by Elan provide significant protection in stroke model

New isocoumarins with antiangiogenic activity claimed by Korean scientists

Somatostatin and neuromedin B receptor agonists and their use

Merck discloses two series of thrombin inhibitors in recent patents

Additional carcinogenicity studies requested by FDA to support Pozen's MT-100 NDA

MMP-13 inhibitors particularly useful for arthritis, atherosclerosis, as claimed by AstraZeneca

NMDA receptor antagonism may be involved in neuroprotective effects of mglu5 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...